Two NICU Tools in Light of New Studies
Discuss the efficacy of nCPAP with a gentler interface.
Dr. Michael McQueen presents "Two NICU Tools in Light of New Studies--the efficacy of nCPAP with a gentler interface". In this new and updated course you'll learn about:
- Discuss high velocity therapy
- Describe the differences between high velocity therapy and high flow nasal cannula (HFNC)
- Discuss how high velocity therapy is a viable alternative to nCPAP for primary respiratory support in neonates
- Understand that the FDA distinguishes between HFNC and high velocity therapy products
This course is AARC accredited for 1 CRCE under the Neonatal-Pediatric (NPS) category.
Michael C. McQueen MD, MBA, FAAP, has over 28 years of clinical and leadership experience. He has served as Regional Medical Director for Envision Healthcare, Medical Director of the NICU at Phoenix Children’s Hospital, as well as several NICUs within the Banner Healthcare System in Phoenix. He has also served as Regional President for Pediatrix Medical Group, and President of Obstetrix Medical Group. Dr. McQueen completed his Pediatric Residency at Phoenix Children’s Hospital / Maricopa Medical Center in Phoenix, AZ, and his Neonatal-Perinatal Medicine Fellowship at the University of Vermont, Burlington, VT. His recent contributions on High-Velocity Nasal Insufflation respiratory support in neonates can be found in J Pulm Respir Med (2014), J Health Economics and Outcomes Research (2015), and J Perinatology (2017). Dr. McQueen is currently Vice President of Medical Affairs at Vapotherm, Inc.